Avalon to reinvest in early-stage assets as Genentech acquires Afraxis license
09:20 EST 29 Jan 2013 | SCRIP
Now that the small San Diego, US biotechnology company Afraxis has signed a global licensing agreement worth up to $187.5 million with Roche's Genentech unit, it will cease to exist as a drug discovery firm, but its "dendritic spine" lab will live o..
Original Article: Avalon to reinvest in early-stage assets as Genentech acquires Afraxis license
More From BioPortfolio on "Avalon to reinvest in early-stage assets as Genentech acquires Afraxis license"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
